| Risdiplam | 401.474
C22H23N7O |  | An oral mRNA splicing modifier used in the treatment of spinal muscular atrophy (SMA). | BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Musculo-Skeletal System / Other Miscellaneous Therapeutic Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Survival Motor Neuron-2-directed RNA Interaction / Survival of Motor Neuron 2 Splicing Modifier |
| Tovorafenib | 506.29
C17H12Cl2F3N7O2S |  | A type II RAF inhibitor used to treat pediatric low-grade glioma with BRAF gene mutations. | B-Raf serine-threonine kinase (BRAF) inhibitors / BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Inducers / Cytochrome P-450 CYP1A2 Inducers (strength unknown) / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring / Sulfur Compounds |
| Avapritinib | 498.57
C26H27FN10 |  | A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors. | Kinase Inhibitor |
| Futibatinib | 418.457
C22H22N6O3 |  | A kinase inhibitor used to treat intrahepatic cholangiocarcinoma in previously treated adults. | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors |
| Tepotinib | 492.583
C29H28N6O2 |  | An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations. | Antineoplastic Agents / Kinase Inhibitor / Proto-Oncogene Proteins c-met, antagonists & inhibitors |
| Vamorolone | 356.462
C22H28O4 |  | A synthetic glucocorticoid used as an anti-inflammatory and immunosuppressant in the management of Duchenne muscular dystrophy (DMD). | Glucocorticoids |
| Pemigatinib | 487.508
C24H27F2N5O4 |  | A kinase inhibitor used to treat locally advanced or metastatic, unresectable cholangiocarcinoma in previously treated adult patients. | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors |
| Gefapixant | 353.4
C14H19N5O4S |  | A P2X3 receptor antagonist that reduces the cough reflex in patients with refractory or unexplained chronic cough. | Amides / BCRP/ABCG2 Substrates / Benzene Derivatives / Cough and Cold Preparations / MATE 1 Substrates / MATE 2 Substrates / MATE substrates / P-glycoprotein substrates / Sulfonamides / Sulfones / Sulfur Compounds |
| Upadacitinib | 380.375
C17H19F3N6O |  | An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. | Selective Immunosuppressants |
| Omidenepag isopropyl | 520.61
C26H28N6O4S |  | An agonist of the prostaglandin EP2 receptor indicated for the reduction of elevated intraocular pressure. | Antiglaucoma Agents / Hypotensive Agents / Ophthalmic Solutions / Ophthalmics / Prodrugs / Pyrazoles / Pyridines / Receptors, Prostaglandin E, EP2 Subtype, agonists / Sulfonamides |
| Aprocitentan | 546.19
C16H14Br2N6O4S |  | An endothelin receptor antagonist used for the treatment of uncontrolled hypertension in patients inadequately controlled on other treatments. | Amides / Antihypertensive Agents / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2C18 Inhibitors / Cytochrome P-450 CYP2C18 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Endothelin Receptor Antagonists / P-glycoprotein substrates / Sulfones / Sulfur Compounds / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT2B7 Inhibitors / UGT2B7 substrates |
| Zanubrutinib | 471.561
C27H29N5O3 |  | A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. | Bruton's tyrosine kinase (BTK) inhibitors / Tyrosine Kinase Inhibitors |
| Daridorexant | 450.93
C23H23ClN6O2 |  | A dual orexin receptor antagonist used to treat insomnia in adults. | Orexin Receptor Antagonists |
| Avacopan | 581.656
C33H35F4N3O2 |  | An orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis. | Complement Inactivating Agents / Selective Immunosuppressants |
| Umbralisib | 571.56
C31H24F3N5O3 |  | A kinase inhibitor used to treat rare forms of refractory lymphoma. | Kinase Inhibitor |
| Voxelotor | 337.379
C19H19N3O3 |  | A drug used to inhibit the polymerization of hemoglobin S, preventing the painful and sometimes lethal vaso-occlusive crises associated with sickle cell disease. | Hematologic Agents |
| Abrocitinib | 323.42
C14H21N5O2S |  | A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. | Agents for Dermatitis, Excluding Corticosteroids |
| Ritlecitinib | 285.351
C15H19N5O |  | A kinase inhibitor used to treat severe alopecia areata in adults and adolescents 12 years and older. | Janus Kinase Inhibitor |
| Mavacamten | 273.336
C15H19N3O2 |  | A myosin inhibitor used to treat obstructive hypertrophic cardiomyopathy. | Amines / Benzene Derivatives / Benzyl Compounds / Cardiac Myosin Inhibitor / Cardiac Therapy / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Pyrimidines / Pyrimidinones |
| Flortaucipir F-18 | 262.278
C16H10FN3 |  | A small lipophilic tracer containing [18F]fluoride capable of crossing the blood-brain barrier and binding to aggregated tau protein; used in PET imaging for the diagnosis of Alzheimer's disease. | Contrast Media |
| Vibegron | 444.535
C26H28N4O3 |  | A beta-3 adrenergic agonist the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. | Adrenergic Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Genito Urinary System and Sex Hormones / Genitourinary Smooth Muscle Relaxants / P-glycoprotein substrates / Pyrimidines / Selective Beta 3-adrenergic Agonists / Urologicals |
| Oliceridine | 386.55
C22H30N2O2S |  | A biased opioid agonist indicated for the management of severe acute pain in adult patients. Through preferential activation of G-protein-coupled signalling pathways, oliceridine provides analgesic effect with a comparable or improved safety profile over conventional opioid agonists. | Ligands |
| Cefiderocol | 752.21
C30H34ClN7O10S2 |  | A cephalosporin antibiotic used in complicated urinary tract infections. | beta Lactam Antibiotics |
| Filgotinib | 425.51
C21H23N5O3S |  | A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. | Janus Kinase Inhibitor / Selective Immunosuppressants |
| Ripretinib | 510.367
C24H21BrFN5O2 |  | A kinase inhibitor used to treat advanced gastrointestinal stromal tumor (GIST). | Kinase Inhibitor |
